Narcolepsy

Key Points

  • Narcolepsy is a central nervous system hypersomnolence disorder with sudden, irresistible sleep episodes during waking hours.
  • Type 1 narcolepsy involves low orexin levels and cataplexy (sudden muscle weakness triggered by emotions).
  • Type 2 narcolepsy involves sudden sleep episodes without cataplexy and with normal orexin levels.
  • Treatment includes stimulant drugs, SSRIs, SNRIs, and TCAs; safety education is essential due to accident risk.

Pathophysiology

Narcolepsy is a central nervous system disorder of sleep-wake regulation. In type 1 narcolepsy, there is a deficiency of the neurotransmitter orexin (hypocretin), which plays a critical role in maintaining wakefulness. This deficiency is thought to result from autoimmune destruction of orexin-producing neurons in the hypothalamus. In type 2 narcolepsy, orexin levels are normal, and the exact pathophysiology is less well understood. The onset is most common between ages 10 and 25 years.

Classification

  • Type 1: Sudden sleep episodes with cataplexy; low orexin levels; may include sleep paralysis and hallucinations.
  • Type 2: Sudden daytime sleep episodes without cataplexy; normal orexin levels; common onset in adolescence.

Clinical Manifestations

  • Excessive daytime sleepiness with sudden, irresistible “sleep attacks.”
  • Cataplexy (type 1): sudden bilateral muscle weakness triggered by strong emotions (laughter, stress, excitement, fear).
  • Hypnagogic or hypnopompic hallucinations (vivid sensory experiences at sleep onset or upon waking).
  • Sleep paralysis (temporary inability to move or speak during transitions between sleep and wakefulness).
  • Disrupted nighttime sleep.

Nursing Assessment

  • Obtain detailed sleep history: frequency of daytime sleep episodes, triggers, associated symptoms.
  • Assess for cataplexy: sudden muscle weakness episodes related to emotional stimuli.
  • Evaluate impact on daily functioning: work performance, driving safety, social relationships.
  • Review polysomnography and multiple sleep latency test (MSLT) results.
  • Assess safety risks: falls from cataplexy, motor vehicle accidents from sleep attacks.

Nursing Interventions

  • Administer prescribed stimulant medications (modafinil, methylphenidate) for daytime sleepiness.
  • Administer prescribed sodium oxybate for cataplexy and nighttime sleep consolidation.
  • Educate about safety: avoid driving or operating machinery during periods of sleepiness; plan short scheduled naps.
  • Promote regular sleep-wake schedules and good sleep hygiene.
  • Provide emotional support; narcolepsy can significantly impact quality of life and self-esteem.
  • Encourage wearing medical alert identification.

Self-Check

  1. What neurotransmitter deficiency is associated with type 1 narcolepsy?
  2. How does cataplexy differ from a seizure?
  3. Why is safety education critical for clients diagnosed with narcolepsy?